UBS lowered the firm’s price target on Treace Medical (TMCI) to $5.85 from $6.50 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMCI:
- Treace Medical downgraded to Neutral from Buy at BTIG
- Treace Medical downgraded to Underweight from Neutral at JPMorgan
- Treace Medical Concepts Reports Q3 2025 Financial Results
- Treace Medical cuts FY25 revenue view to $211M-$213M from $224M-$230M
- Treace Medical reports Q3 EPS (26c), consensus (27c)